Literature DB >> 19433685

Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?

Jennifer R Stark1, Sven Perner, Meir J Stampfer, Jennifer A Sinnott, Stephen Finn, Anna S Eisenstein, Jing Ma, Michelangelo Fiorentino, Tobias Kurth, Massimo Loda, Edward L Giovannucci, Mark A Rubin, Lorelei A Mucci.   

Abstract

PURPOSE Gleason grading is an important predictor of prostate cancer (PCa) outcomes. Studies using surrogate PCa end points suggest outcomes for Gleason score (GS) 7 cancers vary according to the predominance of pattern 4. These studies have influenced clinical practice, but it is unclear if rates of PCa mortality differ for 3 + 4 and 4 + 3 tumors. Using PCa mortality as the primary end point, we compared outcomes in Gleason 3 + 4 and 4 + 3 cancers, and the predictive ability of GS from a standardized review versus original scoring. PATIENTS AND METHODS Three study pathologists conducted a blinded standardized review of 693 prostatectomy and 119 biopsy specimens to assign primary and secondary Gleason patterns. Tumor specimens were from PCa patients diagnosed between 1984 and 2004 from the Physicians' Health Study and Health Professionals Follow-Up Study. Lethal PCa (n = 53) was defined as development of bony metastases or PCa death. Hazard ratios (HR) were estimated according to original GS and standardized GS. We compared the discrimination of standardized and original grading with C-statistics from models of 10-year survival. Results For prostatectomy specimens, 4 + 3 cancers were associated with a three-fold increase in lethal PCa compared with 3 + 4 cancers (95% CI, 1.1 to 8.6). The discrimination of models of standardized scores from prostatectomy (C-statistic, 0.86) and biopsy (C-statistic, 0.85) were improved compared to models of original scores (prostatectomy C-statistic, 0.82; biopsy C-statistic, 0.72). CONCLUSION Ignoring the predominance of Gleason pattern 4 in GS 7 cancers may conceal important prognostic information. A standardized review of GS can improve prediction of PCa survival.

Entities:  

Mesh:

Year:  2009        PMID: 19433685      PMCID: PMC2717753          DOI: 10.1200/JCO.2008.20.4669

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  32 in total

1.  Overdiagnosis of prostatic adenocarcinoma.

Authors:  D G Bostwick; L Chang
Journal:  Semin Urol Oncol       Date:  1999-11

2.  Biological determinants of cancer progression in men with prostate cancer.

Authors:  T A Stamey; J E McNeal; C M Yemoto; B M Sigal; I M Johnstone
Journal:  JAMA       Date:  1999-04-21       Impact factor: 56.272

3.  Prostate cancer and the Will Rogers phenomenon.

Authors:  Peter C Albertsen; James A Hanley; George H Barrows; David F Penson; Pam D H Kowalczyk; M Melinda Sanders; Judith Fine
Journal:  J Natl Cancer Inst       Date:  2005-09-07       Impact factor: 13.506

4.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.

Authors:  A W Partin; M W Kattan; E N Subong; P C Walsh; K J Wojno; J E Oesterling; P T Scardino; J D Pearson
Journal:  JAMA       Date:  1997-05-14       Impact factor: 56.272

5.  Natural history of progression after PSA elevation following radical prostatectomy.

Authors:  C R Pound; A W Partin; M A Eisenberger; D W Chan; J D Pearson; P C Walsh
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

6.  Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta").

Authors:  Fernando J Bianco; Peter T Scardino; James A Eastham
Journal:  Urology       Date:  2005-11       Impact factor: 2.649

7.  Final report on the aspirin component of the ongoing Physicians' Health Study.

Authors: 
Journal:  N Engl J Med       Date:  1989-07-20       Impact factor: 91.245

8.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.

Authors:  Anna Bill-Axelson; Lars Holmberg; Frej Filén; Mirja Ruutu; Hans Garmo; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Juni Palmgren; Hans-Olov Adami; Jan-Erik Johansson
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

9.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

Authors:  A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein
Journal:  JAMA       Date:  1998-09-16       Impact factor: 56.272

10.  Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease.

Authors:  C H Hennekens; J E Buring; J E Manson; M Stampfer; B Rosner; N R Cook; C Belanger; F LaMotte; J M Gaziano; P M Ridker; W Willett; R Peto
Journal:  N Engl J Med       Date:  1996-05-02       Impact factor: 91.245

View more
  155 in total

Review 1.  Focal therapy of prostate cancer: evidence-based analysis for modern selection criteria.

Authors:  Michael R Abern; Matvey Tsivian; Thomas J Polascik
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

2.  Should we abstain from Gleason score 2-4 in the diagnosis of prostate cancer? Results of a German multicentre study.

Authors:  Sabine Brookman-May; Matthias May; Wolf-Ferdinand Wieland; Steffen Lebentrau; Sven Gunia; Stefan Koch; Christian Gilfrich; Jan Roigas; Bernd Hoschke; Maximilian Burger
Journal:  World J Urol       Date:  2010-12-30       Impact factor: 4.226

3.  [The 2014 consensus conference of the ISUP on Gleason grading of prostatic carcinoma].

Authors:  G Kristiansen; L Egevad; M Amin; B Delahunt; J R Srigley; P A Humphrey; J I Epstein
Journal:  Pathologe       Date:  2016-02       Impact factor: 1.011

4.  The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer.

Authors:  Rebecca E Graff; Andreas Pettersson; Rosina T Lis; Natalie DuPre; Kristina M Jordahl; Elizabeth Nuttall; Jennifer R Rider; Michelangelo Fiorentino; Howard D Sesso; Stacey A Kenfield; Massimo Loda; Edward L Giovannucci; Bernard Rosner; Paul L Nguyen; Christopher J Sweeney; Lorelei A Mucci
Journal:  Prostate       Date:  2015-03-01       Impact factor: 4.104

5.  Genome-wide association study of prostate cancer mortality.

Authors:  Kathryn L Penney; Saumyadipta Pyne; Fredrick R Schumacher; Jennifer A Sinnott; Lorelei A Mucci; Peter L Kraft; Jing Ma; William K Oh; Tobias Kurth; Philip W Kantoff; Edward L Giovannucci; Meir J Stampfer; David J Hunter; Matthew L Freedman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-10-26       Impact factor: 4.254

6.  Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993-2004.

Authors:  Katharina Nimptsch; Elizabeth A Platz; Michael N Pollak; Stacey A Kenfield; Meir J Stampfer; Walter C Willett; Edward Giovannucci
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

7.  An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation.

Authors:  Dolores Di Vizio; Matteo Morello; Federica Sotgia; Richard G Pestell; Michael R Freeman; Michael P Lisanti
Journal:  Cell Cycle       Date:  2009-08-27       Impact factor: 4.534

8.  Quantitative imaging of the receptor for advanced glycation end-products in prostate cancer.

Authors:  Christian J Konopka; Marcin Woźniak; Jamila Hedhli; Anna Siekierzycka; Jarosław Skokowski; Rafał Pęksa; Marcin Matuszewski; Gnanasekar Munirathinam; Andre Kajdacsy-Balla; Iwona T Dobrucki; Leszek Kalinowski; Lawrence W Dobrucki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-03-12       Impact factor: 9.236

9.  Prognostic Utility of a New mRNA Expression Signature of Gleason Score.

Authors:  Jennifer A Sinnott; Sam F Peisch; Svitlana Tyekucheva; Travis Gerke; Rosina Lis; Jennifer R Rider; Michelangelo Fiorentino; Meir J Stampfer; Lorelei A Mucci; Massimo Loda; Kathryn L Penney
Journal:  Clin Cancer Res       Date:  2016-09-23       Impact factor: 12.531

10.  A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.

Authors:  Thomas U Ahearn; Andreas Pettersson; Ericka M Ebot; Travis Gerke; Rebecca E Graff; Carlos L Morais; Jessica L Hicks; Kathryn M Wilson; Jennifer R Rider; Howard D Sesso; Michelangelo Fiorentino; Richard Flavin; Stephen Finn; Edward L Giovannucci; Massimo Loda; Meir J Stampfer; Angelo M De Marzo; Lorelei A Mucci; Tamara L Lotan
Journal:  J Natl Cancer Inst       Date:  2015-11-27       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.